OOIR: Observatory of International Research

Papers

(The TQCC of Altex-Alternatives to Animal Experimentation is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Probabilistic risk assessment – the keystone for the future of toxicology	28
NAM-supported read-across: From case studies to regulatory guidance in safety assessment	17
Pyrogen testing revisited on occasion of the 25th anniversary of the whole blood monocyte activation test	13
Guidance document on Good Cell and Tissue Culture Practice 2.0 (GCCP 2.0)	13
Perspectives on the evaluation and adoption of complex in vitro models in drug development: Workshop with the FDA and the pharmaceutical industry (IQ MPS Affiliate)	12
How a GIVIMP certification program can increase confidence in in vitro methods	10
Next-generation risk assessment of chemicals – Rolling out a human-centric testing strategy to drive 3R implementation: The RISK-HUNT3R project perspective	10
The state of the scientific revolution in toxicology	9
Reply to comment “Animal welfare and ethics in the collection of fetal blood for the production of fetal bovine serum”	9
A strategy towards the generation of testable adverse outcome pathways for nanomaterials	8
Characteristics to consider when selecting a positive control material for an in vitro assay	8
On the usefulness of animals as a model system (part I): Overview of criteria and focus on robustness	7
Continuing animal tests on cosmetic ingredients for REACH in the EU	7
Ready for regulatory use: NAMs and NGRA for chemical safety assurance	7
A new approach methodology (NAM) for the prediction of (nor)ibogaine-induced cardiotoxicity in humans	6
Academic application of Good Cell Culture Practice for induced pluripotent stem cells	6
Retrospective analysis of dermal absorption triple pack data	6
Evaluation of an in vitro three-dimensional HepaRG spheroid model for genotoxicity testing using the high-throughput CometChip platform	6
New approach methods supporting read-across: Two neurotoxicity AOP-based IATA case studies	6
Educational use of animals in Europe indicates a reluctance to implement alternatives	5
Leveraging microphysiological systems to address challenges encountered during development of oligonucleotide therapeutics	5
A triangular approach for the validation of new approach methods for skin sensitization	5
Organoid intelligence (OI) – The ultimate functionality of a brain microphysiological system	5
COVID-19 through Adverse Outcome Pathways: Building networks to better understand the disease – 3rd CIAO AOP Design Workshop	5
Replacing fetal bovine serum (FBS) in research and testing	5

Consensus statement from the European Network of 3R Centres (EU3Rnet)	5
On the usefulness of animals as a model system (part II): Considering benefits within distinct use domains	5
Implementing in vitro bioactivity data to modernize priority setting of chemical inventories	5
Limitations of animal epilepsy research models: Can epileptic human tissue provide translational benefit?	5
ToxAIcology - The evolving role of artificial intelligence in advancing toxicology and modernizing regulatory science	5
Predictive performance of next generation human physiologically based kinetic (PBK) model predictions based on in vitro and in silico input data	4
Report of the 1st and 2nd Mystery of Reactive Oxygen Species Conferences	4
A high-throughput and highly automated genotoxicity screening assay	4
U.S. Federal Agency interests and key considerations for new approach methodologies for nanomaterials	4
Proceedings of a workshop to address animal methods bias in scientific publishing	4
A call for a Human Exposome Project	4
Mind the gaps: Prioritizing activities to meet regulatory needs for acute systemic lethality	4
A cell-based alternative to the mouse potency assay for pharmaceutical type E botulinum antitoxins	4
Using the monocyte activation test as a stand-alone release test for medical devices	4
Understanding COVID-19 through adverse outcome pathways – 2nd CIAO AOP Design Workshop	3
Development of a network of carcinogenicity adverse outcome pathways and its employment as an evidence framework for safety assessment	3
COVID-19 – prime time for microphysiological systems, as illustrated for the brain	3
The future of Parkinson’s disease research: A new paradigm of human-specific investigation is necessary… and possible	3
Animal welfare and ethics in the collection of fetal blood for the production of fetal bovine serum	3
Grouping of UVCB substances with dose-response transcriptomics data from human cell-based assays	3
Improving the quality of toxicology and environmental health systematic reviews: What journal editors can do	3
SpheraCosmolife: a new tool for the risk assessment of cosmetic products	3
Application of Immunocompetent Microphysiological Systems in Drug Development: Current Perspective and Recommendations	2
Evaluation of 147 perfluoroalkyl substances for immunotoxic and other (patho)physiological activities through phenotypic screening of human primary cells	2
Novel prediction models for genotoxicity based on biomarker genes in human HepaRGTM cells	2
A microfluidic thyroid-liver platform to assess chemical safety in humans	2
Applications of microphysiological systems to disease models in the biopharmaceutical industry: Opportunities and challenges	2
Comparison of human recombinant protein coatings and fibroblast-ECM to Matrigel for induced pluripotent stem cell culture and renal podocyte differentiation	2
REACH out-numbered! The future of REACH and animal numbers	2
A rodent thyroid-liver chip to capture thyroid toxicity on organ functional level	2
An alternative in vivo model to evaluate pluripotency of patient-specific iPSCs	2
Engagement of scientists with the public and policymakers to promote alternative methods	2
Integrated skin sensitization assessment based on OECD methods (II): Hazard and potency by combining kinetic peptide reactivity and the “2 out of 3” Defined Approach	2
Applying evidence-based methods to the development and use of adverse outcome pathways	2
Dog as the experimental model: Laboratory uses of dogs in the United States	2
Applying a next generation risk assessment framework for skin sensitisation to inconsistent new approach methodology information	2
Application of evidence-based methods to construct mechanism-driven chemical assessment frameworks	2
A survey to assess animal methods bias in scientific publishing	2
Animal metrics: Tracking contributions of new approach methods to reduced animal use	2
How to formulate hypotheses and IATA to support grouping and read-across of nanoforms	2
Exploration of the GARDskin applicability domain: Indirectly acting haptens, hydrophobic substances and UVCBs	2
A human iPSC-based in vitro neural network formation assay to investigate neurodevelopmental toxicity of pesticides	2
Integrated skin sensitization assessment based on OECD methods (III): Adding human data to the assessment	2